Ruthenium-based complexes containing 2-thiouracil derivatives with the chemical formulas trans-[Ru(2TU)(PPh3)2(bipy)]PF6 and trans-[Ru(6m2TU)(PPh3)2(bipy)]PF6 (where 2TU = 2-thiouracil and 6m2TU = 6-methyl-2-thiouracil) inhibited HCC CSCs by targeting NF-κB and Akt/mTOR signaling, causing apoptotic cell death. This evidence concerns the gene MTOR and hepatocellular carcinoma.